Evidence map›Paper›PMID 35753585›Full record

ArticleFree radical biology & medicine2022

Mitochondrial interaction of fibrosis-protective 5-methoxy tryptophan enhances collagen uptake by macrophages.

Sjors Maassen, Harry Warner, Melina Ioannidis, Jack Jansma, Hugo Markus, Sahar El Aidy, María-Dolores Chiara, Jose Luis Chiara, Larissa Maierhofer, Helen Weavers and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Free radical biology & medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Tracing NADCell reports · 2026
    Article
  2. Article
  3. Article
  4. Tracing NADResearch square · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. A quantitativeMethodsX · 2023
    Article
  10. Development of [Journal of medicinal chemistry · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Sjors MaassenDepartment of Molecular Immunology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, 050, the Netherlands.
Harry WarnerDepartment of Molecular Immunology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, 050, the Netherlands.
Melina IoannidisDepartment of Molecular Immunology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, 050, the Netherlands.
Jack JansmaDepartment of Host-Microbe Interactions, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, 050, the Netherlands.
Hugo MarkusDepartment of Molecular Immunology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, 050, the Netherlands.
Sahar El AidyDepartment of Host-Microbe Interactions, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, 050, the Netherlands.
María-Dolores ChiaraInstitute of Sanitary Research of the Principado de Asturias, Oviedo, Spain; CIBERONC (Network of Biomedical Research in Cancer), Madrid, Spain.
Jose Luis ChiaraInstitute of General Organic Chemistry, IQOG-CSIC, Madrid, Spain.
Larissa MaierhoferInstitute of General Organic Chemistry, IQOG-CSIC, Madrid, Spain.
Helen WeaversSchool of Biochemistry, Biomedical Sciences, University of Bristol, Bristol, BS8 1TD, United Kingdom.
Geert van den BogaartDepartment of Molecular Immunology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, 050, the Netherlands; Department of Medical Biology and Pathology, University Medical Center Groningen, University of Groningen, 050, the Netherlands. Electronic address: g.van.den.bogaart@rug.nl.
University of Groningen · NLInstituto de Química Orgánica General · ESGobierno del Principado de Asturias · ESUniversity Medical Center Groningen · NLUniversity of Bristol · GB

Funding

European Research Council 862137Wellcome Trust 208762/Z/17/Z
6 · The paper itself

Abstract

5-methoxy tryptophan (5-MTP) is an anti-fibrotic metabolite made by fibroblasts and epithelial cells, present in a micromolar concentrations in human blood, and is associated with the progression of fibrotic kidney disease, but the mechanism is unclear. Here, we show by microscopy and functional assays that 5-MTP influences mitochondria in human peripheral blood monocyte-derived macrophages. As a result, the mitochondrial membranes are more rigid, more branched, and are protected against oxidation. The macrophages also change their metabolism by reducing mitochondrial import of acyl-carnitines, intermediates of fatty acid metabolism, driving glucose import. Moreover, 5-MTP increases the endocytosis of collagen by macrophages, and experiments with inhibition of glucose uptake showed that this is a direct result of their altered metabolism. However, 5-MTP does not affect the macrophages following pathogenic stimulation, due to 5-MTP degradation by induced expression of indole-amine oxygenase-1 (IDO-1). Thus, 5-MTP is a fibrosis-protective metabolite that, in absence of pathogenic stimulation, promotes collagen uptake by anti-inflammatory macrophages by altering the physicochemical properties of their mitochondrial membranes.

Indexed as

MacrophagesTryptophanCollagenFibrosisHumansMitochondriaCollagenTryptophan5-Methoxy tryptophanFibrosisIDOInflammationMacrophageMetabolismMitochondria

Identifiers

PMID35753585
PMCPMC7614693
OpenAlexW4283379208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.